Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation

被引:9
作者
Christiansen, D
Loveland, B
Kyriakou, P
Lanteri, M
Rubinstein, E
Gerlier, D [1 ]
机构
[1] Fac Med Laennec, VPV, CNRS, UCBL UMR 5537, F-69372 Lyon 08, France
[2] Austin Res Inst, Heidelberg, Vic 3084, Australia
[3] Hop Paul Brousse, INSERM, U268, Villejuif, France
基金
英国医学研究理事会;
关键词
CD46; CD55; C3b deposition; membrane cofactor protein;
D O I
10.1016/S0161-5890(01)00002-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric proteins using membrane cofactor (CD46) and decay accelerating factor (DAF or CD55) were generated to further investigate the functional domains involved in the regulation of human serum complement. Following activation of the classical pathway, the isolated substitution of CD46 SCR III (x 3DAF) exhibited a modest regulatory activity comparable to that of CD46. The isolated substitution of CD46 SCR IV (x 4DAF), and the combined CD46 SCR III + IV substitutions (x 3/4DAF) were essentially as efficient as DAF. No regulation of C3b deposition was observed with the combined CD46 SCR I + II substitutions (x 1/2DAF). When tested after activation of the alternative pathway, both the x 3DAF and x 3/4DAF chimeras failed to regulate C3b deposition, while the x 4DAF chimera still displayed some activity. In contrast to that observed following classical pathway activation, the x 1/2DAF chimera exhibited a similar efficiency to wild type CD46 and DAF in controlling C3b deposition. Using SCR specific antibodies, the regulatory activity of the x 1/2DAF chimera against the alternative pathway was mapped to the first three distal SCR (i.e. DAF 1, DAF 2 and CD46 III). These data demonstrate that several combinations of SCR domains from two related complement regulators can result in functional molecules, and reveal a novel and cryptic functional role for DAF SCR1. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:687 / 696
页数:10
相关论文
共 51 条
[1]  
Accardo P, 1996, J IMMUNOL, V157, P4935
[2]  
ADAMS EM, 1991, J IMMUNOL, V147, P3005
[3]   SOLUTION STRUCTURE OF A PAIR OF COMPLEMENT MODULES BY NUCLEAR-MAGNETIC-RESONANCE [J].
BARLOW, PN ;
STEINKASSERER, A ;
NORMAN, DG ;
KIEFFER, B ;
WILES, AP ;
SIM, RB ;
CAMPBELL, ID .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 232 (01) :268-284
[4]   DECAY-ACCELERATING FACTOR (CD55), A GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED COMPLEMENT REGULATORY PROTEIN, IS A RECEPTOR FOR SEVERAL ECHOVIRUSES [J].
BERGELSON, JM ;
CHAN, M ;
SOLOMON, KR ;
STJOHN, NF ;
LIN, HM ;
FINBERG, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :6245-6248
[5]   A cluster of positively charged amino acids in the C4BP α-chain is crucial for C4b binding and factor I cofactor function [J].
Blom, AM ;
Webb, J ;
Villoutreix, BO ;
Dahlbäck, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) :19237-19245
[6]  
Brodbeck WG, 1996, J IMMUNOL, V156, P2528
[7]   Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack [J].
Brodbeck, WG ;
Mold, C ;
Atkinson, JP ;
Medof, ME .
JOURNAL OF IMMUNOLOGY, 2000, 165 (07) :3999-4006
[8]   Crystal structure of two CD46 domains reveals an extended measles virus-binding surface [J].
Casasnovas, JM ;
Larvie, M ;
Stehle, T .
EMBO JOURNAL, 1999, 18 (11) :2911-2922
[9]   Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates [J].
Charreau, B ;
Ménoret, S ;
Tesson, L ;
Azimzadeh, A ;
Audet, M ;
Wolf, P ;
Marquet, R ;
Verbakel, C ;
Ijzermans, J ;
Cowan, P ;
Pearse, M ;
d'Apice, A ;
Soulillou, JP ;
Anegon, I .
MOLECULAR MEDICINE, 1999, 5 (09) :617-630
[10]   Interaction of CD46 with measles virus: accessory role of CD46 short consensus repeat IV [J].
Christiansen, D ;
Loveland, B ;
Kyriakou, P ;
Lanteri, M ;
Escoffier, C ;
Gerlier, D .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :911-917